The global risk approach should be better applied in french hypertensive patients: A comparison between simulation and observation studies

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Marchant, Ivanny ^a,b,c   Nony, Patrice ^b,c,e   Cucherat, Michel ^c   Boissel, Jean Pierre ^g,h   Thomas, S Randall ^f   Bejan Angoulvant, Theodora ^b,c,d,e   Laugerotte, Alexandra ^b,c,d   Kahoul, Riad ^c,g,h   Gueyffier, François ^b,c,d,e  

^a UNIVERSIDAD DE VALPARAÍSO   (Chile)

^b IMTh Institute for Theoretical Medicine   (France)

^c UNIVERSITÉ LYON 1   (France)

^d INSERM   (France)

^e HOSPICES CIVILS DE LYON   (France)

^f UNIVERSITÉ PARIS SACLAY   (France)

^g Novadiscovery   (France)

^h Novacare   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; AWARENESS; BLOOD PRESSURE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; FRANCE; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PUBLIC HEALTH; RISK ASSESSMENT; SEX DIFFERENCE; SIMULATION; COMPARATIVE STUDY; COMPUTER SIMULATION; DRUG EFFECT; HEALTH CARE PLANNING; INTERNATIONAL COOPERATION; MIDDLE AGED; PATHOPHYSIOLOGY; PRESCRIPTION; PREVALENCE; RISK FACTOR;

ANTIHYPERTENSIVE AGENT;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; COMPUTER SIMULATION; DRUG PRESCRIPTIONS; FEMALE; FRANCE; HEALTH PLAN IMPLEMENTATION; HEALTH PLANNING GUIDELINES; HUMANS; HYPERTENSION; INTERNATIONALITY; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS;

EID: 79952302948     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017508     Document Type: Article

References (26)

1. Massol J, Puech A, Boissel JP, (2007) How to anticipate the assessment of the public health benefit of new medicines? Therapie 62: 427-435.
2. Inserm-CépiDc (Centre d'épidémiologie sur les causes médicales de décès) (2008) Principales causes de décès. INSEE Available: http://www.insee.fr/fr/themes/tableau.asp?ref_id=natfps06205 Accessed 2011 Feb 10.
3. Pyorala K, De Backer G, Graham I, Poole-Wilson P, Wood D, (1994) Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis 110: 121-161.
4. (1985) Hypertension prevalence and the status of awareness, treatment, and control in the United States. Final report of the Subcommittee on Definition and Prevalence of the 1984 Joint National Committee. Hypertension 7: 457-468.
5. (1993) 1993 guidelines for the management of mild hypertension. Memorandum from a World Health Organization/International Society of Hypertension meeting. Guidelines Subcommittee of the WHO/ISH Mild Hypertension Liaison Committee. Hypertension 22: 392-403.
6. Pyorala K, Wood D, (1998) Prevention of coronary heart disease in clinical practice. European recommendations revised and reinforced. Eur Heart J 19: 1413-1415.
7. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, et al. (2003) European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 24: 1601-1610.
8. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, et al. (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24: 987-1003.
9. Anaes, (2004) Méthodes d'évaluation du risque cardio-vasculaire global. ANAES(Agence nationale d'accréditation et d'évaluation en santé).
10. Marshall T, (2003) Coronary heart disease prevention: insights from modelling incremental cost effectiveness. BMJ 327: 1264-1268.
11. Marshall T, Rouse A, (2002) Resource implications and health benefits of primary prevention strategies for cardiovascular disease in people aged 30 to 74: mathematical modelling study. BMJ 325: 197-202.
12. Marchant I, Boissel JP, Kassai B, Bejan T, Massol J, et al. (2009) SCORE should be preferred to Framingham to predict cardiovascular death in French population. Eur J Cardiovasc Prev Rehabil 16: 609-615.
13. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, et al. (2007) European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 14 (Suppl 2): S1-113.
14. Godet-Thobie H, Vernay M, Noukpoape A, Salanave B, Malon A, et al. (2008) Mean blood pressure level and prevalence of hypertension in 18 to 74 year-old adults, ENNS Survey 2006-2007. InVS pp. 478-482.
15. Richard JL, (1988) [The MONICA project. A WHO research project in cardiovascular diseases]. Rev Epidemiol Sante Publique 36: 325-334.
16. Law MR, Wald NJ, (2002) Risk factor thresholds: their existence under scrutiny. BMJ 324: 1570-1576.
17. Probstfield JL, (2003) How cost-effective are new preventive strategies for cardiovascular disease? Am J Cardiol 91: 22G-27G.
18. Institut National des Statistiques et des Etudes Economiques (2004) Structure par âge des populations féminine et masculine. Available: http://www.insee.fr/fr/themes/tableau.asp?reg_id=0&ref_id=NATnon02150. Accessed 2010 Apr 2.
19. Gourdy P, Ruidavets JB, Ferrieres J, Ducimetiere P, Amouyel P, et al. (2001) Prevalence of type 2 diabetes and impaired fasting glucose in the middle-aged population of three French regions- The MONICA study 1995-97. Diabetes Metab 27: 347-358.
20. Mould D, (2003) Defining Covariate Distribution Models for Clinical Trial Simulation. In: Kimko H, Duffull S, editors. Simulation for Designing Clinical Trials A Pharmacokinetic-Pharmacodynamic Modeling Perspective New York Marcel Dekker pp. 33-53.
21. Marques-Vidal P, Rodondi N, Bochud M, Pecoud A, Hayoz D, et al. (2008) Predictive accuracy and usefulness of calibration of the ESC SCORE in Switzerland. Eur J Cardiovasc Prev Rehabil 15: 402-408.
22. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, et al. (2007) 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28: 1462-1536.
23. Kassai B, Gueyffier F, Boissel JP, Boutitie F, Cucherat M, (2003) Absolute benefit, number needed to treat and gain in life expectancy: which efficacy indices for measuring the treatment benefit? J Clin Epidemiol 56: 977-982.
24. Gueyffier F, Froment A, Gouton M, (1996) New meta-analysis of treatment trials of hypertension: improving the estimate of therapeutic benefit. J Hum Hypertens 10: 1-8.
25. R Development Core Team (2008) R: A Language and Environment for Statistical Computing Vienna, Austria R Foundation for Statistical Computing.
26. Venables WN, Ripley BD, (2002) Modern Applied Statistics with S New York Springer.